Entera Bio Ltd Stock Price, News & Analysis

Entera Bio Ltd (NASDAQ: ENTX) announced the filing of multiple U.S. patent applications to bolster its intellectual property and support future development of its oral delivery platform technology. This technology aims to enhance bioavailability and reduce drug costs compared to existing oral delivery systems for peptides. Additionally, the company is focusing on specific molecules, such as parathyroid hormone and glucagon-like peptides, for various therapeutic indications. CEO Spiros Jamas highlighted the potential for strategic partnerships to advance their innovations.

Entera Bio Ltd (NASDAQ: ENTX) will report its business and financial results for Q1 2022 on May 12, 2022, at 8:30 AM EDT. The company focuses on developing orally delivered large-molecule therapeutics to address significant unmet medical needs. Entera's advanced candidates include EB613 for osteoporosis and EB612 for hypoparathyroidism, which are currently in clinical development. The company also collaborates with biopharmaceutical firms, including Amgen Inc., licensing its proprietary drug delivery technology.

Entera Bio Ltd (NASDAQ: ENTX), a pioneer in orally delivered large molecule therapeutics, announced its participation in the Maxim Virtual Growth Conference on March 30, 2022, at 10:30 AM EDT, featuring a fireside chat format.

Following the event, a webcast replay will be accessible on Entera's investor relations website. Entera focuses on addressing unmet medical needs with its cutting-edge oral drug delivery technology, particularly for osteoporosis and hypoparathyroidism. The company recently completed a phase 2 study for its lead candidate, EB613.

Entera Bio Ltd. (NASDAQ: ENTX) reported 2021 financial results, highlighting a revenue increase to $571,000 from $365,000 in 2020. The company incurred an operating loss of $12.2 million, up from $11.2 million the previous year. Key developments include positive Phase 2 results for EB613 in osteoporosis and EB612 for hypoparathyroidism. Entera plans to initiate Phase 3 trials for EB613 and a new formulation for EB612 in 2022. The company holds $24.9 million in cash as of year-end, projecting an operating loss of $25-$30 million for 2022.

Entera Bio Ltd (NASDAQ: ENTX) will report its financial and business results for the year ended December 31, 2021, on March 8, 2022, at 6:30 AM EST. Following the results, a conference call will be held at 8:30 AM EST, where management will discuss the findings and take questions from participants. The company specializes in orally delivered large molecule therapeutics, focusing on conditions with significant unmet medical needs. Its lead candidates are EB613 for osteoporosis and EB612 for hypoparathyroidism, currently in clinical development.

Entera Bio Ltd (NASDAQ: ENTX) announced that CEO Spiros Jamas, Sc.D., will present a company overview at the Aegis Capital Corp. Virtual Conference on February 23, 2022, at 3:30 PM Eastern. The presentation will detail the pivotal Phase 3 study for its lead drug candidate, EB613, aimed at being the first oral bone-building drug for osteoporosis. More details here.

Entera Bio Ltd (NASDAQ: ENTX) announced plans to initiate a multi-national Phase 3 trial in 2022 for EB613, an oral formulation of human parathyroid hormone aimed at treating osteoporosis. Following a successful End-of-Phase 2 meeting with the FDA, the company confirmed that a fracture study is not required, with lumbar spine BMD at 12 months as the primary endpoint. If approved, EB613 would become the first oral anabolic osteoporosis treatment, potentially expanding patient access. With over 200 million osteoporosis patients globally, Entera anticipates significant market growth.

Entera Bio Ltd. (NASDAQ: ENTX) announced its financial results for Q3 2021, revealing revenues of $406,000, significantly up from $144,000 in Q3 2020. The Phase 2 clinical trial for EB613 showed promising results in increasing bone mineral density in osteoporosis patients, leading to plans for a Phase 3 trial in 2022. The company has a strong cash position of $27.4 million, which supports its operations through Q4 2022. Additionally, operating expenses decreased, but the net comprehensive loss widened to $17.1 million, up from $7.7 million in the same period last year.

Entera Bio Ltd. (NASDAQ: ENTX) announced promising results from preclinical in vivo studies showcasing its proprietary oral delivery technology, which demonstrates enhanced absorption for large biologic drugs. This technology underpins Entera's lead product, EB613, currently in Phase 3 clinical development for osteoporosis, with a pivotal study set for 2022. Researchers reported a significant increase in blood PTH levels using a dual mechanism combining protease inhibitors and permeation enhancers, making oral dosing a viable alternative to injections, which may improve patient compliance and treatment outcomes.